What is Kisspeptin-10?

Kisspeptin-10 (KP-10) is a biologically active peptide made up of ten amino acids (a decapeptide). It acts as a central regulator of reproductive hormones by controlling the release of GnRH in the brain. It is created through enzymatic cleavage from the precursor peptide Kisspeptin-54 (Metastin), which is encoded by the KISS1 gene. By binding to the KISS1R receptor (GPR54), Kisspeptin-10 stimulates the body's own release of the gonadotropins LH (luteinizing hormone) and FSH (follicle-stimulating hormone) [1][2].

As the shortest naturally occurring peptide variant, Kisspeptin-10 has the full biological activity of the original molecule. In experimental peptide research, KP-10 is preferred because it is much easier to produce synthetically than the larger Kisspeptin-54. Neither in the EU nor in the USA does Kisspeptin-10 have regulatory approval as a finished medicinal product [2].

How is Kisspeptin-10 used in research?

In scientific and clinical studies, Kisspeptin-10 is primarily given intravenously at doses of 0.1 to 1.0 nmol/kg body weight, either as a bolus or an infusion, and less commonly subcutaneously [1][2]. A study by Yeung et al. (2026) showed that repeated subcutaneous injection over 12 days also effectively stimulates gonadotropin release in healthy men [9].

On the peptide gray market, Kisspeptin-10 is mostly offered as a lyophilized dry powder in glass vials. Users dissolve the powder with sterile bacteriostatic water (BAC water) before subcutaneous injection. For self-administration, there are no officially reviewed dosing schedules or safety data outside of controlled clinical studies.

The biological half-life of Kisspeptin-10 is only a few minutes after intravenous administration. Because of this rapid breakdown, clinical studies mainly rely on continuous infusions or closely spaced multiple injections to produce measurable and stable hormone levels [2].

How are reconstitution and dosing of Kisspeptin-10 calculated?

Reconstitution and dosing calculations for Kisspeptin-10 are based on dissolving the peptide powder exactly in a defined amount of bacteriostatic water to determine the peptide concentration per milliliter. The following overview shows the calculation methods and mixing ratios used in scientific studies, purely for informational purposes.

How does reconstitution of Kisspeptin-10 work?

The freeze-dried Kisspeptin-10 powder is carefully reconstituted with sterile BAC water, where the chosen liquid volume determines the resulting concentration per milliliter:

Vial size	BAC water	Concentration
1 mg	1 mL	1,000 µg/mL
1 mg	2 mL	500 µg/mL
3 mg	3 mL	1,000 µg/mL

Example calculation for determining dosage

A standard intravenous dose in scientific studies is about 0.3 nmol/kg body weight [1]. The molar dose calculation for a test subject weighing 70 kg works as follows:

0.3 nmol/kg × 70 kg = 21 nmol total amount of Kisspeptin-10
Molar mass of Kisspeptin-10: approx. 1,302 g/mol
21 nmol × 1,302 g/mol ≈ 27 µg peptide mass
At a concentration of 1,000 µg/mL, this corresponds to an injection volume of 27 µL, administered with a precise microsyringe

For subcutaneous injection, the study by Yeung et al. (2026) used higher doses because bioavailability under the skin is lower compared to intravenous administration [9]. The exact dose values from this publication can be found under the PubMed ID PMID 42549827.

Note: These details document experimental study doses and are not a dosing recommendation. For precise preparation and volume calculation of peptide solutions, the Injection Calculator is available. Further guidance on proper reconstitution and storage can be found in the Instructions.

What is the mechanism of action of Kisspeptin-10?

Kisspeptin-10 binds specifically to the KISS1R receptor on neuroendocrine cells in the hypothalamus and stimulates the pulsatile release of gonadotropin-releasing hormone (GnRH). GnRH prompts the pituitary gland to release LH and FSH into the bloodstream [1][2].

The KISS1/KISS1R signaling axis is considered the biochemical master switch for reproductive maturation and fertility. Without the KISS1/KISS1R system, puberty does not start, and fertility is not possible - this has been shown in patients who carry mutations in the KISS1R gene and suffer from delayed or absent puberty [1].

In addition, the activity of kisspeptin neurons is closely linked to energy metabolism and energy availability. During severe calorie deficit or underweight, the neurons register the energy shortage and reduce GnRH release to temporarily shut down reproductive processes to protect the organism [3].

What results do clinical studies on Kisspeptin-10 show?

The effect of Kisspeptin-10 and Kisspeptin-54 on hormone secretion and egg maturation has been investigated in several clinical studies. The key research findings at a glance:

LH and FSH stimulation: A single intravenous dose of kisspeptin leads to an immediate rise in serum levels of LH and FSH in healthy men and women [1][2].
Egg maturation in IVF: In phase 2 studies, Kisspeptin-54 was successfully used in women at high risk for ovarian hyperstimulation syndrome (OHSS) to trigger egg maturation - a potentially safer alternative to the usual hCG trigger [4][5][6].
Hypothalamic amenorrhea: Subcutaneously administered Kisspeptin-54 reactivated gonadotropin release in functional amenorrhea, although repeated doses led to a reduced effect (tachyphylaxis) [7][8].
Repeated subcutaneous KP-10: Yeung et al. (2026) demonstrated that 12 days of subcutaneous Kisspeptin-10 administration in healthy men produces sustained stimulation of gonadotropins [9].
Polycystic ovary syndrome (PCOS): Preliminary study data suggest that kisspeptin can induce gonadotropic responses and support ovulation in PCOS patients [10][11].

What doses of kisspeptin have been studied?

Clinical studies use different peptide variants and dosing protocols depending on the research goal. The following table summarizes the schedules documented in scientific publications:

Variant	Route	Dose	Frequency/Duration	Study population
KP-10	intravenous	0.1-1.0 nmol/kg	Single bolus	Healthy subjects [1][2]
KP-10	subcutaneous	not publicly documented*	Repeated for 12 days	Healthy men [9]
KP-54	intravenous	0.4-1.6 nmol/kg	Single bolus	IVF patients [4][5]
KP-54	subcutaneous	6.4 nmol/kg	2× per week, 8 weeks	Hypothalamic amenorrhea [8]

*The exact dosing parameters of the study by Yeung et al. can be found in the primary publication.

This overview serves as scientific documentation of published study data and is not a dosing guide. Outside of clinical trials, there is no officially approved standard dose for Kisspeptin-10.

What side effects and risks does Kisspeptin-10 have?

Kisspeptin-10 and Kisspeptin-54 have proven to be largely well tolerated in controlled studies, but they do have specific pharmacological risks. The documented side effects and limitations include:

Tachyphylaxis: With repeated administration, the effect can diminish - the body responds less and less to the peptide. This has been observed especially with long-term subcutaneous use of Kisspeptin-54 [7].
Hormonal overstimulation: Since kisspeptin stimulates the release of LH and FSH, too high a dose can lead to overstimulation of the ovaries (OHSS risk in IVF patients) [5].
Very short half-life: The rapid breakdown within minutes requires closely spaced injections or continuous infusions to maintain stable effective levels [2].
Lack of long-term data: There are currently no long-term studies on the safety of repeated Kisspeptin-10 administration over months or years.

What is the legal and approval status of Kisspeptin-10?

Kisspeptin-10 does not have medicinal product approval in either the European Union (EU) or the USA. It only has the status of an experimental research substance. While Kisspeptin-54 is being studied in clinical phase 2 trials for IVF, Kisspeptin-10 products offered online from the gray market are not subject to any pharmaceutical quality control. Important criteria for assessing dubious sources are explained in the guide Protection when ordering.

What research gaps exist for Kisspeptin-10?

Lack of standard dosing: For Kisspeptin-10, there is no validated human dosage outside of scientific study protocols.
Subcutaneous pharmacokinetics: Data on subcutaneous bioavailability and duration of action are only incompletely studied compared to intravenous data.
Long-term safety: Reliable studies on toxicity, receptor interaction, and tolerability with longer use are completely lacking.
Comparison KP-10 vs. KP-54: Direct comparative studies on the biological potency and stability of the different kisspeptin isoforms are rare.
Prevention of tachyphylaxis: Methods to avoid receptor desensitization with long-term use have not yet been scientifically solved.

A related peptide in the field of reproductive hormones is Gonadorelin, which acts as synthetic GnRH directly on the pituitary GnRH receptor and stimulates the release of LH and FSH.

Evidence at a glance

Research status

Kisspeptin is currently in clinical phase 2 research and does not yet have drug approval. Most human studies focus on kisspeptin-54, particularly for triggering egg maturation in artificial fertilization (IVF trigger), in hypothalamic amenorrhea (missed periods due to a lack of hormonal control), and in polycystic ovary syndrome (PCOS). The peptide variant kisspeptin-10 was given subcutaneously (under the skin) to healthy men over 12 days in a recent study [9].

Human evidence

Kisspeptin, in the forms KP-10 and KP-54, reliably triggers the release of the hormones LH and FSH in human studies with healthy men and women [1][2]. In phase 2 studies, kisspeptin-54 was tested as a trigger for egg maturation in IVF patients at high risk for ovarian hyperstimulation syndrome (OHSS) [4][5][6]. In women with hypothalamic amenorrhea (missed periods), subcutaneous kisspeptin-54 increased gonadotropin secretion, while chronic use led to tachyphylaxis (a diminishing effect) [7][8]. In healthy men, KP-10 was specifically tested subcutaneously over 12 days [9]. In polycystic ovary syndrome (PCOS), gonadotropic responses and partial restoration of ovulation were observed [10][11].

Dosages in studies & practice

There is no official kisspeptin dosage or validated standard dose outside of clinical studies. In studies on KP-10, researchers investigated intravenous doses of 0.1-1.0 nmol/kg body weight as a single bolus [1][2], and a subcutaneous KP-10 administration over 12 days in healthy men [9] (exact dose to be taken from the publication). For kisspeptin-54, clinical investigations document dosages of IV 0.4-1.6 nmol/kg for IVF trigger [4][5] and SC 6.4 nmol/kg twice weekly over 8 weeks for hypothalamic amenorrhea [8].

Risks & side effects

In studies, the peptide generally shows good tolerability, but it does carry specific application risks. With repeated administration, tachyphylaxis can occur, which means the effect diminishes over time [7]. In IVF patients, there is a risk of ovarian hyperstimulation syndrome (OHSS) [5]. Also, the very short half-life of just a few minutes makes consistent stimulation difficult [2], and long-term safety data is still completely lacking.

Research gaps

There is no approved human dose for the peptide KP-10. Its subcutaneous bioavailability has not been studied enough, and there are no controlled long-term studies over months or years. Most clinical data come from KP-54, not KP-10, because direct comparative studies are missing. Also unresolved is how to treat tachyphylaxis (the rapid adaptation to the active substance).

Editorial, sourced from primary literature - not medical advice.

Related peptides

Sources

← Back to peptides

Common use from studies